Log in

NASDAQ:DYAIDyadic International Stock Price, Forecast & News

+0.28 (+3.26 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $8.88
50-Day Range
MA: $8.88
52-Week Range
Now: $8.88
Volume97,149 shs
Average Volume129,958 shs
Market Capitalization$243.93 million
P/E RatioN/A
Dividend YieldN/A
Dyadic International, Inc., a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. Dyadic International, Inc. has a research collaboration with Mitsubishi Tanabe Pharma Corp. to express two therapeutic compounds using C1 production platform; and the Sanofi-Aventis Deutschland GmbH to express the potential of its C1 technology to produce various types of therapeutic compounds for manufacturing protein-based vaccine and biologic drugs; and research collaboration with global biotech company to explore the potential of its C1 technology to produce an active moiety. The company was founded in 1979 and is headquartered in Jupiter, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:DYAI



Sales & Book Value

Annual Sales$1.68 million
Book Value$1.32 per share


Net Income$-8,310,000.00
Net Margins-523.65%


Market Cap$243.93 million
Next Earnings Date8/13/2020 (Confirmed)
OptionableNot Optionable
+0.28 (+3.26 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DYAI News and Ratings via Email

Sign-up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Dyadic International (NASDAQ:DYAI) Frequently Asked Questions

How has Dyadic International's stock been impacted by COVID-19 (Coronavirus)?

Dyadic International's stock was trading at $4.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DYAI stock has increased by 88.1% and is now trading at $8.88.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Dyadic International?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyadic International in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Dyadic International

When is Dyadic International's next earnings date?

Dyadic International is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Dyadic International

How can I listen to Dyadic International's earnings call?

Dyadic International will be holding an earnings conference call on Thursday, August 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Dyadic International's earnings last quarter?

Dyadic International, Inc (NASDAQ:DYAI) announced its quarterly earnings data on Thursday, May, 14th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.06. The biotechnology company earned $0.32 million during the quarter, compared to the consensus estimate of $2.07 million. Dyadic International had a negative return on equity of 22.87% and a negative net margin of 523.65%.
View Dyadic International's earnings history

What price target have analysts set for DYAI?

2 equities research analysts have issued 1 year price objectives for Dyadic International's stock. Their forecasts range from $11.00 to $14.00. On average, they anticipate Dyadic International's share price to reach $12.50 in the next year. This suggests a possible upside of 40.8% from the stock's current price.
View analysts' price targets for Dyadic International

Has Dyadic International been receiving favorable news coverage?

News headlines about DYAI stock have been trending negative on Monday, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dyadic International earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about Dyadic International

Are investors shorting Dyadic International?

Dyadic International saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 1,600,000 shares, a decline of 7.5% from the July 15th total of 1,730,000 shares. Based on an average trading volume of 279,000 shares, the days-to-cover ratio is currently 5.7 days. Currently, 8.3% of the shares of the stock are sold short.
View Dyadic International's Short Interest

Who are some of Dyadic International's key competitors?

What other stocks do shareholders of Dyadic International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dyadic International investors own include Endeavour Silver (EXK), Hecla Mining (HL), Silvercorp Metals (SVM), Endeavour Silver (EDR), Mandalay Resources (MND), Alibaba Group (BABA), Alphabet (GOOG), Pfizer (PFE), Gilead Sciences (GILD) and Exxon Mobil (XOM).

Who are Dyadic International's key executives?

Dyadic International's management team includes the following people:
  • Mr. Mark A. Emalfarb, Founder, CEO, Pres & Director (Age 63)
  • Ms. Ping Wang Rawson, Chief Accounting Officer & Principal Financial Officer (Age 43)
  • Mr. Matthew S. Jones, Managing Director of Bus. Devel. & Licensing (Age 41)
  • Dr. Ronen Tchelet, VP of Research & Bus. Devel. (Age 61)
  • Ms. Ana Gómez Rodriguez, Sec. of the Board

What is Dyadic International's stock symbol?

Dyadic International trades on the NASDAQ under the ticker symbol "DYAI."

Who are Dyadic International's major shareholders?

Dyadic International's stock is owned by a variety of institutional and retail investors. Top institutional investors include New York State Common Retirement Fund (0.11%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.05%), SG Americas Securities LLC (0.04%), UBS Group AG (0.02%) and Strs Ohio (0.02%). Company insiders that own Dyadic International stock include Barry Buckland and Ronen Tchelet.
View institutional ownership trends for Dyadic International

Which major investors are buying Dyadic International stock?

DYAI stock was acquired by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Nelson Van Denburg & Campbell Wealth Management Group LLC, SG Americas Securities LLC, Strs Ohio, and UBS Group AG.
View insider buying and selling activity for Dyadic International

How do I buy shares of Dyadic International?

Shares of DYAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Dyadic International's stock price today?

One share of DYAI stock can currently be purchased for approximately $8.88.

How big of a company is Dyadic International?

Dyadic International has a market capitalization of $243.93 million and generates $1.68 million in revenue each year. The biotechnology company earns $-8,310,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. Dyadic International employs 6 workers across the globe.

What is Dyadic International's official website?

The official website for Dyadic International is www.dyadic.com.

How can I contact Dyadic International?

Dyadic International's mailing address is 140 INTRACOASTAL POINTE DRIVE SUITE 404, JUPITER FL, 33477. The biotechnology company can be reached via phone at 561-743-8333 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.